Cargando…

Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study

BACKGROUND: Emollients are a mainstay of treatment for dry skin conditions. In the UK, prescribers are usually expected to follow local National Health Service (NHS) formularies. A previous study in 2018 showed that the recommended emollients across England and Wales varied widely. Evidence has sinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Amakye, Nana Yaa T., Chan, Jonathan, Ridd, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545708/
https://www.ncbi.nlm.nih.gov/pubmed/35340047
http://dx.doi.org/10.1111/ced.15197
_version_ 1784804879715270656
author Amakye, Nana Yaa T.
Chan, Jonathan
Ridd, Matthew J.
author_facet Amakye, Nana Yaa T.
Chan, Jonathan
Ridd, Matthew J.
author_sort Amakye, Nana Yaa T.
collection PubMed
description BACKGROUND: Emollients are a mainstay of treatment for dry skin conditions. In the UK, prescribers are usually expected to follow local National Health Service (NHS) formularies. A previous study in 2018 showed that the recommended emollients across England and Wales varied widely. Evidence has since emerged that bath additives provide no additional clinical benefit in eczema. AIM: To compare emollient formularies and guidelines in England. METHODS: Clinical Commissioning Group (CCG) formularies and guidelines were identified in April–May 2021, compiled and then analysed descriptively. RESULTS: In total, 105 CCGs, 72 emollient formularies and 47 emollient prescribing guidelines were identified. There were internal inconsistencies between formularies and their accompanying guidelines in 19% of cases. The majority (68%) of formularies/guidelines were organized using a ranking system. In total, 126 different leave‐on emollients were named. Creams and ointments were universally available and were the most recommended first‐line types. Cost was more likely than patient choice to be recommended as a criterion for selecting which emollient to prescribe. Aqueous cream was the leave‐on emollient most commonly not recommended. Nearly three‐quarters (74%) of formularies stated that bath additives should not be prescribed. CONCLUSION: All CCGs in England have an emollient formulary/guideline, but there is still great variability between them in their recommendations. Although the number of formularies/guidelines has reduced since 2017, there has been an increase in the total number of unique recommended leave‐on emollients. Most CCGs are no longer recommending bath emollients for eczema.
format Online
Article
Text
id pubmed-9545708
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95457082022-10-14 Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study Amakye, Nana Yaa T. Chan, Jonathan Ridd, Matthew J. Clin Exp Dermatol Original Articles BACKGROUND: Emollients are a mainstay of treatment for dry skin conditions. In the UK, prescribers are usually expected to follow local National Health Service (NHS) formularies. A previous study in 2018 showed that the recommended emollients across England and Wales varied widely. Evidence has since emerged that bath additives provide no additional clinical benefit in eczema. AIM: To compare emollient formularies and guidelines in England. METHODS: Clinical Commissioning Group (CCG) formularies and guidelines were identified in April–May 2021, compiled and then analysed descriptively. RESULTS: In total, 105 CCGs, 72 emollient formularies and 47 emollient prescribing guidelines were identified. There were internal inconsistencies between formularies and their accompanying guidelines in 19% of cases. The majority (68%) of formularies/guidelines were organized using a ranking system. In total, 126 different leave‐on emollients were named. Creams and ointments were universally available and were the most recommended first‐line types. Cost was more likely than patient choice to be recommended as a criterion for selecting which emollient to prescribe. Aqueous cream was the leave‐on emollient most commonly not recommended. Nearly three‐quarters (74%) of formularies stated that bath additives should not be prescribed. CONCLUSION: All CCGs in England have an emollient formulary/guideline, but there is still great variability between them in their recommendations. Although the number of formularies/guidelines has reduced since 2017, there has been an increase in the total number of unique recommended leave‐on emollients. Most CCGs are no longer recommending bath emollients for eczema. John Wiley and Sons Inc. 2022-05-26 2022-08 /pmc/articles/PMC9545708/ /pubmed/35340047 http://dx.doi.org/10.1111/ced.15197 Text en © 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Amakye, Nana Yaa T.
Chan, Jonathan
Ridd, Matthew J.
Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title_full Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title_fullStr Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title_full_unstemmed Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title_short Emollient prescribing formularies and guidelines in England, 2021: a cross‐sectional study
title_sort emollient prescribing formularies and guidelines in england, 2021: a cross‐sectional study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545708/
https://www.ncbi.nlm.nih.gov/pubmed/35340047
http://dx.doi.org/10.1111/ced.15197
work_keys_str_mv AT amakyenanayaat emollientprescribingformulariesandguidelinesinengland2021acrosssectionalstudy
AT chanjonathan emollientprescribingformulariesandguidelinesinengland2021acrosssectionalstudy
AT riddmatthewj emollientprescribingformulariesandguidelinesinengland2021acrosssectionalstudy